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This paper investigates the determinants of success in the development of new
drugs. In specic, it explores the factors of success in drug development programs
at dierent stages of innovation process. We use economies of scale, scope, R&D
competition and technological spillovers as explanatory variables and test whether
the eect of these variables on the success of a project diers in relation to the
discovery and development stages of innovation, respectively. Our main nding is
that spillovers, including spillovers from collaboration, are important in explaining
the success of projects during the discovery stage of innovation, while in the later
development stage, the eects of competition outweigh any benets from spillovers.
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Understanding rm evolution is not possible without looking at its innovation activities.
A rm's position among the competitors and its long-term performance depend, among
other things, on how successful it is in the introduction of new products and processes.
The uncertain nature of innovation implies an amount of risk in relation to rm's
research and development activities. Yet, it is believed that innovation (or R&D) success
can be stimulated through utilizing economies of scale and scope (Teece, 1980; Panzar
and Willig, 1981). In this sense, bigger rms have an advantage in distributing the overall
costs of R&D over a larger amount of sales. Other factors of success include experience
(Nerkar and Roberts, 2004; Macher and Boerner, 2006), alliances (Danzon et al., 2005)
and market size (Acemoglu and Linn, 2004).
It is natural to conceptualize innovation as a process going through dierent stages
(Knight, 1967). One very general sequence for product R&D is discovery (or invention),
followed by development and then market launching (or application). These stages can
be applied to pharmaceutical innovation as documented in the literature (for example,
Arora et al. (2009) and (Macher and Boerner, 2006)).
Each of these stages, however, requires dierent skills for successful implementation.
For example, discovery requires creativity and the ability to generate new ideas, especially
since what determines success here is spillovers from within a rm, as well as from other
rms (Henderson and Cockburn, 1996). Market launching and adoption success, on the
other hand, tend to be more dependent on the level of competition and the experience of
the rm on that market (Nerkar and Roberts, 2004).
This paper empirically analyzes the impact of factors such as economies of scale and
scope, competition and spillovers on the success of innovation projects. It, furthermore,
focuses on the changes in the eects of these factors during innovation process. The
rationale behind this change is that an innovation process represents an evolution of a
project from an idea to a marketable product. We assumed that technological factors
are more important for innovation success in the early stages of innovation, whereas
competition is considered more relevant in the later stages of the innovation process. The
results of empirical analysis generally conrm our proposed intuition.
The analysis is performed on a set of new drug projects developed by rms in the
pharmaceutical industry. The drug research and development process can be divided
into a clearly separated sequence of stages: discovery, pre-clinical development, clinical
development, application and approval. This makes new drug development an ideal topic
for studying the innovation process.
The remainder of the paper is organized as follows: section 2 contains a summary of
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construction are described in sections 3 and 4; empirical strategy is presented in section
5; the results of the empirical analysis are reported in section 6; and section 7 concludes.
2 Success in innovation: Formulation of hypotheses
2.1 The process of drug innovation
The process of drug discovery and development can be divided into several stages. It
starts with drug discovery, when a new chemical entity is created. Then, the long process
of testing the new substance, rst on animals (Pre-clinical development), and then on
humans (Clinical trials), follows. During these testing stages, the new substance can be
further developed in order to improve the eciency and safety of the drug. In general,
the overall success of the innovation depends on the quality of the starting substance, as
well as on the research conducted during pre-clinical and clinical trials. If clinical trials
are successful, the rm developing this drug submits an application in order to receive
ocial approval, which is necessary to produce and distribute the drug over-the-counter.
After approval is received, the new drug can then be manufactured and launched in the
market. Finally, after these stages some further development still may take place, such
as additional research to improve the drug and/or continued generic development of the
drug.
Figure 1: Stages of Drug Innovation
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of each stage. As the gure illustrates, the process of drug innovation generally takes
form ten to fteen years. Of this time span, about three to six years are spent on drug
discovery and pre-clinical testing, and six to seven years on the development of the new
drug during the clinical testing stage. Although the result of the last stage, FDA (Food
and Drug Administration) review, is essentially an indicator of the ultimate success in
drug innovation process, at the same time, success during the intermediate (before market
launching) stages of drug innovation can be judged by how far a particular drug project
advances in its development: in other words, the closer a drug project is to market launch,
the more successful it has been.
2.2 Hypotheses
The intention of this paper is to show how various factors impact on project success diers
across innovation stages, since these require dierent knowledge, experience, resources,
etc. The underlying intuition is based on an understanding of an innovation project as
an evolving entity within a dynamic context. Since innovation is a process, the dynamic
denition of any project could be its development level. Therefore, the comparison of
dierent innovations can be carried out before they are launched in the market by looking
at how advanced the stage of any given innovation is.
One important observation about the innovation process is that it starts with the
creation of something new (discovery) and ends when the new product, incorporating the
created novelty, is introduced to consumers (market launching). These two aspects of
the innovation process imply that a successful innovation should be both technologically
advanced, to pass the discovery stage, and attractive for consumers on the market. The
success of an innovation project is thus dened in terms of both its technological and
market characteristics.
The rst stage of innovation, discovery (or invention), implies the creation of a new
composition, device, process, or, in the case of drug innovation, the creation of a new
molecule or solution. In a science-based industry, such as the pharmaceutical industry, the
discovery of a new drug is highly dependent on technology. For instance, it is described by
Nightingale (2000) that the process of drug discovery (the rst stage of drug innovation) is
dened in terms of technological traditions. On the other hand, the launch of a new drug
on the market is regarded as an entry problem, where such factors as competition and
market size play a crucial role (Kyle, 2006). Consequently, the success of an innovation
project could be attributed to dierent factors, depending on its stage.
1Source: Pharmaceutical Research and Manufacturers of America, http://www.phrma.org/
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though innovation is the evolutionary process of an idea into a product or a process, most
of the studies analyzing innovation success are concerned with only one of the innovation
stages at a time, without reecting the dynamic nature of innovation phenomena. From
one side, innovation success could be considered as a result of market launching. In this
case, the success of an innovation is connected to the market success of the new product.
Therefore, the factors determining innovation success are mostly associated with those
which are related to market entry, such as market size, competition, rm size, as a proxy
for the availability of nancial resources, and connections (Brouwer and Kleinknecht,
1996; Link, 1987; Kraft, 1989; Kyle, 2006). However, when innovation is considered as
an invention, the results of either the discovery stage of innovation or patent application
can be treated as indicators of innovative success or failure. In this case, technological
factors, such as research economies of scale and scope, technological spillovers and knowl-
edge could be regarded as important factors for success (Henderson and Cockburn, 1996;
Cockburn and Henderson, 2001; Jae, 1986; Nesta and Saviotti, 2005; Smith et al., 2005).
The dynamics of the determinants of innovation success have not yet been analyzed
in the literature. At the same time, some preliminary conclusions can already be made
from comparing dierent studies. For example, two separate research, Henderson and
Cockburn (1996); Cockburn and Henderson (2001), explore the eect of the economies of
scale and scope on research productivity, which must be correlated with innovative success
as productive projects tend to be successful ones, at dierent stages of innovation: drug
discovery and drug development. The results of these two studies dier, however, hinting
that there exist some dynamics within the impact of seemingly similar factors on the
success of R&D projects over the course of the innovation process.
Danzon et al. (2005) and Macher and Boerner (2006) analyze projects in drug devel-
opment stage instead of focusing on the entire innovation process. While Macher and
Boerner (2006) refer to the development stage as a period, Danzon et al. (2005) divide
the development stage into three phases of clinical trials and argue that the success rates
of pharmaceutical R&D dier across the phases of drug development. Indeed, the latter
study (i.e. Danzon et al. (2005)) shows that returns on overall rm experience are large
and positive for phases II and III of clinical trials, whereas the returns on experience dur-
ing phase I of clinical trials are small. Another nding of this research is that there are
positive knowledge spillovers across rms during the phase I of clinical trials. Conversely,
the productivity in phases II and III is negatively related to an industry-wide experience.
The explicit argument that there is a selection mechanism operating between innova-
tion stages is expressed in Arora et al. (2009). They analyze the projects going through
discovery. After discovery stage, these projects are selected to conduct clinical trials (drug
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in drug development. Their argument is that newly discovered drugs are selected into
development stage according to the believes of a rm's personnel about the future success
of these drugs. Although the intent of Arora et al. (2009) was to study whether large
rms are more innovative, they also emphasize that the understanding of rm innovation,
in fact, goes beyond simply accounting for economies of scale and scope, also including
strategic selection.
Economies of scale and scope
The eect of the economies of scale and scope on the productivity in research2 is the
main question in Henderson and Cockburn (1996) and Cockburn and Henderson (2001).
However, these two studies analyze dierent stages of innovation. While Henderson and
Cockburn (1996) is concerned with the drug discovery stage, Cockburn and Henderson
(2001) explore the drug development stage. The rst study reveals that productivity
during drug discovery is related to economies of scale and scope. In other words, larger
research eorts are more productive at the rm level. At the same time, economies
of scope are more signicant at the project level. On the contrary to the rst study,
(Cockburn and Henderson, 2001) explain the research performance of projects during the
development stage by returns to scope, rather than returns to scale, both at the level of
a rm. However, the measures of scope become insignicant when controlling for rm
xed eects, suggesting that dierent levels of development success may be related to
inter-rm dierences in organization and management.
The results of Henderson and Cockburn (1996) and Cockburn and Henderson (2001)
support the idea that the successful implementation of dierent stages of the R&D process
relies on various factors. Specically, the comparison between the outcomes of these
two papers suggests that economies of scope are more important in discovery than in
development. One rationale behind this nding could be that the discovery stage is
aimed at the creation of new knowledge. Therefore, spillovers between dierent knowledge
elds can play an important role in the discovery stage. In other words, if a diverse array
of R&D projects is conducted in one rm, economies of scope can arise due to positive
internal spillovers together with a rm's ability to incorporate the knowledge from related
elds into an R&D project (Henderson and Cockburn, 1996).
To summarize, economies of scope in innovation arise from internal knowledge spillovers.
Therefore, rms with diversied innovation activities (implying the possibility of internal
knowledge spillovers) could benet in their R&D through the exchange of ideas across
2Research productivity is related to the success in innovation. In fact, research productivity can
be transformed into an indicator of innovation success by treating more productive innovations more
successful ones, and vise versa.
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discovery can be more important than market factors, we expect that economies of scope
play an important role in drug discovery.
Hypothesis 1: Economies of scope have a stronger eect on the success of R&D
projects during the earlier stages of innovation, i.e. in discovery stage.
The process of pharmaceutical R&D is aected by economies of scale (DiMasi et al.,
1995). Economies of scale arise from signicant xed costs. For example, these costs
exist in the discovery stage because of the necessity of running research laboratories and
maintaining a high quality of the personnel. By the same token, the development stage
(clinical trials) needs legal and regulatory expertise (DiMasi et al., 1995). Since rms
with larger research budgets can manage these xed costs more easily, scale economies
can be expected to be an important factor in the success of drug projects.
We claim, however, that scale economies may be less important in the stage of drug
development compared to drug discovery. This claim is supported by the fact that drug
development can be outsourced to a contract research organization, which specializes in
the organization of clinical trials. Therefore, scale economies in research might have a
lower importance and even become insignicant in the development stage. Moreover,
if established rms are more selective (Arora et al., 2009), then the benets from scale
economies during the development stage may be not important: in other words, if large
rms only pass better projects into the development stage, the success of an innovation
project will depend more on rm characteristics, other than the overall research eort.
Furthermore, some empirical evidence suggests that it is also possible that scale economies
could aect the success of an innovation negatively due to "diseconomies of scale", as
found by Danzon et al. (2005) during the third stage of clinical trials (development
stage).
Consequently, we expect that the eect of scale economies is more important for
project success in the discovery stage than in development. Moreover, economies of scale
are expected to have a positive impact on the success of an R&D project in the discovery
stage.
Hypothesis 2: The economies of scale correlate positively with R&D success on the
discovery stage of innovation.
External spillovers and competition
Economies of scale and scope refer to the internal structure of a rm and its innovation
activities. At the same time, the sources of innovation expand beyond rm borders.
External technological spillovers from other rms and organizations are generally regarded
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Jae (1986); Teece (1992)).
The knowledge of rms in the same research area enriches a rm's own knowledge.
Therefore, other rms knowledge could be helpful in idea implementation: for instance,
a rm could gain from the research of other rms through imitation and collaboration.
Imitation occurs when other rms are unable to perfectly protect their knowledge, while
in collaboration, the knowledge of two or several rms is shared. At the same time,
both imitation and collaboration allow a rm to extend its knowledge beyond rm's
borders. Therefore, these two channels of spillovers may provide better opportunities for
the generation of rm's own ideas (Bondt, 1997; Teece, 1992). Consequently, spillovers
from other rms, and collaboration spillovers ,in particular, should be especially benecial
in the discovery stage of innovation.
Thus, the success in the discovery stage of innovation is aected by technological
spillovers, because the main features of a new product are dened during this stage. On
the contrary, the development stage is devoted to testing a newly discovered product and
improving its features. Furthermore, in the approval phase (for drugs), the technological
environment is even less important. Therefore, it can be predicted that external spillovers
are more important in the early phases of R&D, specically in the discovery stage.
Hypothesis 3: External spillovers are more important for innovation success in the
discovery stage.
Innovation is the transformation of a new idea into a marketable product. Therefore,
potential demand has long been regarded as one of the driving forces for innovation
(for example, Schmookler (1962)). Hence, omitting demand-related factors from the
analysis of the innovation process would mean neglecting the very nature of innovation
as comprising both technological advances and consumer demand characteristics.
Although market demand often triggers a search for new technologies and products,
even before discovery takes place, market factors, such as competition, may not be rel-
evant in the discovery stage. The irrelevance of competition in the discovery stage of
innovation is explained by the fact that there may not yet exist a market for the new
product when the discovery stage is conducted. Moreover, the discovery stage is just the
beginning of innovation process. To illustrate, conducting an R&D project from discovery
to development and market launch takes a long time: for example, drug innovation can
take thirteen to fteen years (Dranove and Meltzer, 1994). Consequently, as innovation is
a highly uncertain process, it is unlikely that market factors would be taken into account
thirteen years prior to market launch.
Therefore, market competition should be more important after discovery is nished.
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are selected into development according to rm management expectations about the
success future projects. Moreover, looking at innovation as a process of information
acquisition under uncertainty (DiMasi et al., 1995; Gino et al., 2006) allows us to conclude
that during the development stage, while the future product is being tested and improved,
it should be possible to collect the information on this future product and its attributes.
Therefore, a rm management, at this point, can better understand the properties of
the developed product and thus better estimate its competitive position relative to other
products, as well as to dene into which market it should be launched in.
All in all, the change of a perspective on an R&D project, from a technological to a
market related, should aect the characteristics of the projects that are most important
for the explaining of projects success. Attributes of a project, which are benecial for its
success in the discovery stage, such as collaboration, can aect project success negatively
in the development stage, due to a potential conict of interests by the collaborating
sides. With regard to spillovers in general, although innovation by other rms might
create the potential for spillovers, and thereby benet that rm's own innovation success,
these innovating rms are also pursuing a similar goal of launching an innovative product
on the market. Therefore, they can be considered as competitors once the product is
dened, in other words, when it is in its development stage.
Consequently, our last hypothesis is formulated in a way that reects that an R&D
project is considered as a competitive good in the development stage. On the other hand,
a technological perspective on the project prevails in the discovery stage.
Hypothesis 4: The project success is explained by competition in the later stages of
the innovation process.
3 Data
The dataset on drug innovation projects, which are conducted by rms in the pharmaceu-
tical industry, was acquired from the BioPharmInsight3 website. This website provides
information on the development of new drugs worldwide. The data have been collected
at the end of 2007, and represents a snapshot of the progress of projects from 1983.
The dataset contains only project updates, meaning that only the last stage of their
development is reported. As the process of drug discovery and development is a fairly
standardized procedure, we claim that in order to reach a given reported stage, a drug
project would need to have passed each of the previous stages. Moreover, if no further
3http://www.innata5.com/biopharm/
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progressing to the next innovation stage, or at least that its development is quite slow.
A slow progress in drug development is usually a sign of the low quality of a project or
of its high complexity, both indicating a highly probable failure for the project.
The information for a project in this dataset is updated as soon as the project moves
to the next stage of innovation. In other words, each project is reported on the latest
stage of its development meaning that all previous stages have been successfully passed.
For example, if it is reported that project A is at phase III of clinical trials, this project
would have gone through the stages of development, preclinical testing, as well as phase
I and phase II of clinical trials.
Table 1: Example of R&D Project Data
Last Update Company Therapeutic Area Stage Partners
2000-09 3M PHARMACEUTICALS Respiratory Approved yes
2000-11 3M PHARMACEUTICALS Infectious Diseases Phase III yes
2002-07 3M PHARMACEUTICALS Immune System Discovery
2002-07 3M PHARMACEUTICALS Pain Phase III
2002-07 3M PHARMACEUTICALS Respiratory Discovery
2003-03 3M PHARMACEUTICALS Infectious Diseases Pre-Clinical
2005-09 3M PHARMACEUTICALS Cancer Phase III yes
2005-09 3M PHARMACEUTICALS Genitourinary Phase I yes
Table 1 gives an example of the data about projects. Here rm name, the type of
project (therapeutic area), the stage of project development and whether the project is
developed in collaboration is signied. In the table, the company "3M Pharmaceuticals"
have reported two projects in 2000: the project in respiratory have been approved; the
project in infectious diseases have been on the phase III of clinical trials. Moreover, both
projects have been developed in collaboration.
Therefore, the data reveals the phase of drug development for each project. The phases
in the original data are categorized into seven groups: discovery, pre-clinical development,
the three subsequent phases of clinical trials, ling an application with the proper dug
authority (for example, the FDA in the United States) to be considered for approval, and
approval. For our analysis, the stages of drug innovation have been aggregated into three
major groups: discovery and preclinical testing, development (includes clinical trials),
and approval. This division is reected in gure 1. Table 2 explains the reassignment of
the stages.
In the data, each rm is assigned to a set of drug development projects. Each of
these projects belongs to one of thirteen therapeutic areas. A therapeutic area is dened
according to a specic body system or a general disease group (for example, "Central
4Later, we introduce the precise time lag, based on the estimates of the duration of the various stages
of drug innovation.
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Original stages Aggregate stages
Drug Discovery Discovery
Pre-Clinical tests Discovery
Phase I clinical trials Development
Phase II clinical trials Development
Phase III clinical trials Development
Filed application Adoption
Approved Adoption
nervous system" or "Infectious diseases") for which the drug project is being developed.
Therefore, therapeutic area indicates the type of an innovation project, or, in other words,
the area in which this research project is being conducted.
Although in the original data a project might be developed by a rm, university or
research institute, only rms are selected for our analysis. The rms selected are mostly
big pharmaceutical rms, belonging to the industry "Chemicals and allied products" in
the standard industrial classication (SIC).
The total number of projects for which we could clearly determine the innovation
phase is about 1800. These projects are spread across dierent innovation stages. The
majority of these projects (more than 60%) are in the development stage, about 20% are
in the discovery stage and less than 20% have been approved or are in the process of
being approved (adoption stage).
4 Variables
Innovation success
Our aim is to measure the innovation success of an R&D project at dierent stages
of innovation. As progress to the next innovation stage means that the previous stage
has been completed, advancement to the next stage is considered to demonstrate project
success. Consequently, success in one of the innovation stages is our dependent variable.
To compare dierent stages, we will run two separate estimations for the success of
a project during the discovery and development stage (see section 5). Accordingly, there
will be two dependent variables: success in development and success in discovery. Each
of these variables is represented as being binary: i.e. is equal to one if a project succeeded
in a corresponding stage, and zero otherwise.
Since the denition of our dependent variable requires that the success of on R&D
project is clearly distinguished from its failure, we had to crop some observations, for
which it was not clear whether the project succeeded or not. Since accomplishing an
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duration of the stages), we cannot regard projects, which are reported in the last years
(2001-2007) as either a success or a failure. However, we only can distinguish failure from
success with certainty if a project has not progressed to the next stage after a long delay.
For example, if a project is reported to have been in the discovery stage since 1987, it
means that this project has still not progressed to the development and later stages in
2007. In other words, there has been no progress in 20 years. Given that the maximum
time needed to complete an innovation stage is 7 years, this project can be appropriately
considered as a failure. However, if a project is reported to be in the discovery stage in
2005, we do not yet know whether it has failed to move further, because completion of
the discovery stage can take up to six years (see gure 1).
The duration of the discovery stage (which consists of both drug discovery and pre-
clinical tests) is three to six years and the duration of the development stage (Phase I,
II, and III clinical trials) is three to seven years (see gure 1 for duration of the stages).
Therefore, in order to prevent a bias towards the projects with a higher speed of progress,
we truncate the data. To do so, we only consider projects which have been reported in the
period from 1983 to 2001. This truncation assures that no progress has been made before
2007 for any project. Hence, in this truncated sample we can interpret the reported stage
of development of every project as the stage, during which this project was withdrawn
from the innovation process. Depending on the stage, this withdrawal can be interpreted
as a success or failure.
We rely on the gure 1 in our assessment of the duration of the stages. However, to
check whether our sample corresponds to the estimations of Pharmaceutical Research and
Manufacturers of America association (PhRMA)5, we estimated the duration of stages for
our sample. According to this estimation, it takes about two and a half years on average
to move between any two subsequent stages. Moreover, it takes, at most, six-seven years
to complete any one stage. Therefore, the duration of project development for our sample
is consistent with the durations recorded by the PhRMA.
Scale and scope economies
In the previous research, scale economies have been found to be signicant at the level
of overall R&D eorts of a rm (Henderson and Cockburn, 1996). Since in this paper we
analyze the innovation projects of a rm, we also consider scale economies at the level
of an overall innovative activity of a rm . Therefore, the measure of the eect of scale
economies is a gure represented by the total number of innovation projects in a rm.
On the other side, the measure of the economies of scope should take into account
5http://www.phrma.org/
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number of dierent therapeutic areas where a rm conducts research is relevant. It is also
important to capture the distribution of rm eorts across those projects. Therefore, we
utilize entropy as a measure of the evenness of distribution of dierent projects within a
rm innovation portfolio. For a more even is the distribution of rm innovative eorts
across dierent therapeutic areas, entropy will be lower, and vice versa.
If Sk is the fraction of projects of type k of the total projects by a rm, then the
project entropy (and consequently, our measure of scope economies) can be calculated
according to equation 1. In the equation, projects are considered similar if they belong
to the same therapeutic area.




External spillovers and competition
The number of rms in the industry is a potential source of spillover. The intensity
of how spillovers aect innovation success will depend on the ease of imitation and the
network structure of the industry. However, the more peers working in the similar area,
the higher should be the opportunity to gain from the research of others, through collab-
oration or imitation of ideas and products. Therefore, if spillover opportunities exist, the
number of rms performing research in the similar therapeutic area will positively aect
the probability of research success.
The potential problem with interpreting the number of rms solely as a spillover pool
is that the rms innovating in the same industry are also potential competitors in the
market of developed and launched products. Furthermore, from the product competition
point of view, the number of rms conducting R&D in the same industry reects the
severity of competition. Consequently, how the success of one rm in R&D aects the
future gains from operating in this industry for all other rms, depends on whether the
eect of technological spillovers prevails competition. Therefore, the eect of the variable
"the number of competitors" on the dependent variable (success) can be expected to
change from positive to negative during the innovation process, because in the rst stages
of innovation the eect of external spillovers will be more important than competition.
On the contrary, competition is crucial during the development stage, product approval
and market launching.
In order to separate spillovers due to collaboration from spillovers captured by the
number of rms in the same therapeutic area, we introduce the variable "collaboration".
This variable is binary: it is equal to one if the project is developed in collaboration, and
zero otherwise.
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tration of innovation projects among rms in a therapeutic area. According to Scherer
(1967), the allocation of more resources into R&D can decrease the duration of innovation
process. Therefore, a high degree of research concentration may be desired to improve the
probability of innovation success. Consequently, rms allocating more eorts in one ther-
apeutic area are expected to be potentially more successful. This implies, that developing
a project in an industry with high research concentration (number of R&D projects by
one rm) means a potentially lower probability of success, due to the presence of stronger
competitors. On the other hand, from the external spillovers perspective, more successful
peers can aect a rm's research in a positive way, if it is relatively easy to learn from
them. Hence, similar to the number of rms in the industry, it can be expected that the
eect of research concentration on project success will change in the course of innovation.
Specically, when spillovers are more important, it should have a positive eect on the
probability of success. In the later stages of innovation, this eect becomes negative when
competition is prevailing.
Experience
Experience has been found to aect innovative performance by Danzon et al. (2005)
and Macher and Boerner (2006). However, we do not have any hypothesis on why the
magnitude of experience on innovative success would vary during the innovation process.
Therefore, we will use experience as a control variable. Innovation experience of a rm
in a therapeutic area is measured by the past number of projects conducted by this rm
in this therapeutic area.
5 Empirical strategy
Our data was collected in 2007 and it reects the state of projects reported between 1983
and 2007. Therefore, we assume that if the project has not been updated within a certain
period after the last update, then it has failed in the last reported stage. Since the sample
covers projects till 2001, each project is given at least six years to move to the next stage.
The stages of innovation reported in the data are aggregated into three groups, reecting
discovery, development and adoption6.
For each project in the sample we determined whether it was a success or a failure.
Therefore, our variable of interest is binary. The binary nature of this variable allows
us to utilize a logit model for empirical estimation. In this estimation, the dependent
variable is the probability of success.
6See previous section for the reassignment of stages.
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Jena Economic Research Papers 2010 - 045It is important to mention that, because stages in R&D process are sequential, the
probability of project success is conditional on the event that this project has passed the
previous stage.
Let hti be the probability of success for a project i during stage t, given that no failure
has occurred during the previous interval s:
hti = Pr(yti = 1jysi = 1;s < t) (2)
In order to utilize this conditional probability in our estimation, we divide the sample
on the projects which reached the discovery stage and those that reached the development
stage. Consequently, the probability of success in the discovery stage is estimated on the
sample of all projects that at least reached discovery stage (these are all projects in our
sample). Furthermore, projects that failed in discovery are excluded from the sample
for estimating the probability of success in development. In other words, we used only
those projects that reached the development stage of innovation for the estimation of the
success probability in this stage.
Therefore, two series of logit regression estimation are performed on two dierent
samples of projects: those that reached the discovery stage, and those that reached the
development stage. In order to observe the dierence in the eect of the explanatory
variables on the probability of success between dierent innovation stages, we compare
the coecients between logit models for these two samples. The sign of the coecient in
a logit model is the sign of the partial eect of the explanatory variable on the probability
of the outcome. For the purpose of this analysis the interpretation of the results based
only on the coecients signs is sucient.
One last remark on the empirical strategy is that we expect that some unobserved
characteristics of a rm may aect the probability of project success. This problem is
addressed by utilizing a clustered errors correction. In the sample, multiple projects can
be conducted by one rm. Therefore, we assumed clustered errors in each regression in
order to take into account possible correlation between them.
6 Results
Table 3 reports the results of the logit estimation. Each estimation is performed twice:
for the discovery and the development stages respectively. The results are reported in
table 3 in pairs: the same model is applied rst to explain success in the discovery stage
and then in the development stage.
Models (1) and (2) in table 3 contain a control variable "experience". Model (1)
reports the results for the regression of the probability of success in the discovery stage
15




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Jena Economic Research Papers 2010 - 045whereas model (2) does so for the probability of success in the development stage. Mod-
els (3) and (4) include scale and scope economies to better explain success rates in the
discovery and development stages correspondingly. Since some signicant correlation
has been observed between pairs of variables, such as scope and scale economies, and
research concentration and competition (see table 4 for correlation), two interaction vari-
ables were constructed in order to capture many ore complicated relationships. One of
these variables (scale*scope) is included in models (3) and (4). Models (5) and (6) are
logit estimations of probability of success in the discovery and development stages, re-
spectively. In theses models, the probability of success is explained by external spillovers
and competition variables such as collaboration, concentration, number of competitors
and the interaction between the last two. The last two models assume both internal and
external determinants of the innovation success as regressors.
One can already notice the dierence between the two innovation stages from the
coecients of the control variable in models (1) and (2). Specically, projects, conducted
by rms which have more experience, tend to succeed more often in the discovery stage
of drug innovation. On the other hand, they seem to be less successful in the develop-
ment stage. In other words, the probability of project failure (as opposed to success) in
discovery decreases with the experience of a rm in the therapeutic area of the project.
On the other hand, failure during development stage is more likely for more experienced
rms.
Economies of scope (listed as "scope") shows signicant coecients in explaining
projects success in both the discovery and development stage of innovation. Coecients
of this variable are positively signicant in models (4) and (8), and negatively signicant
in model (3). Therefore, projects conducted by rms with diverse R&D portfolios are less
likely to succeed in the discovery stage (model (3)) and are on average more successful in
the development stage (models (4) and (8)). The rst result supports the idea that rms
eliminate projects after the discovery stage (Arora et al., 2009). Furthermore, the positive
coecient in the second case suggests that projects, which reached the development
stage, tend to fail less when conducted by rms with diverse R&D projects portfolios.
Consequently, economies of scope positively aect the success of a project in development.
By success in development, we mean that the project did not fail in development and
advanced to the next stage of adoption. This result contradicts hypothesis 1, namely
that economies of scope are more important at the beginning of the innovation process.
Economies of scale (listed as "scale") are signicant in models (3) and (4). The
coecient on this variable is positive and signicant in explaining the projects success in
the drug discovery stage (model (3)) and negatively signicant in the development stage
(model (4)). Hence, the dierences in the signs of the coecients suggest that there
17
Jena Economic Research Papers 2010 - 045are economies of scale in discovery and diseconomies of scale in development stages of
innovation. In other words, their eect on the success of R&D projects varies during
the innovation process. However, when we control for competition and external spillovers
variables, the variable "scale" loses its signicance in explaining the probability of success
(models (7) and (8)).
The coecient on the interaction between scale and scope is negative for the discovery
stage, meaning that the impact of economies of scale on the probability of innovative
success in discovery stage of innovation becomes smaller when a rm has a diverse R&D
portfolio. In other words, rms with large and diversied R&D portfolios experience
projects failure in the discovery stage more often than rms with large and less diversied
R&D portfolios. On the other hand, rms with large and diversied R&D portfolios tend
to be more successful in the development stage. The interaction between scale and scope
loses its signicance in models (7) and (8).
The measures of external spillovers and competition are correlated (table 4 in Ap-
pendix), and deliver a similar result when included into regressions separately. The results
of separate inclusion of these variables into regressions suggest that external spillovers
prevail in the discovery stage, while competition factors are signicant in explaining the
probability of success in the development stage7.
Concentration positively aects the probability of success in discovery, but has a
negatively signicant coecient in the regression for the development stage (models (5)-
(8)). Hence, a high research concentration among rms conducting innovation in the
same therapeutic area is correlated with a higher success rate in the discovery stage. At
the same time, a large number of projects per rm has a negative eect on the probability
of success during the development stage. This result is in line with our expectations and
satises both hypothesis 3 and 4. Therefore, concentration favors technological spillovers
in the discovery stage, but can be considered as a sign of stronger competitors in the
development stage.
The variable "number of competitors" is negatively signicant in explaining the prob-
ability of success in the discovery stage of innovation (models (5) and (7)). On the other
hand, models (6) and (8) deliver a positively signicant coecient for the number of com-
petitors. Consequently, this variable behavior does not coincide with the expectations
reected in hypothesis 3 and 4. Specically, "number of competitors" positively aects
the probability of success in the development stage, meaning that spillover eect is strong
in this stage.
The interaction term between concentration and the number of competitors shows a
positively signicant coecient when explaining the probability of success in discovery
7See Table 5 in Appendix.
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Jena Economic Research Papers 2010 - 045(models (5) and (7)). This result suggests that when both the concentration and the
number of competitors in a therapeutic area are large, projects succeed more often. As
for the results of the regressions for the development stage, a high concentration, along
with a large number of competitors decreases the likelihood of success (negative coecient
on the interaction term in models (6) and (8)).
The variable for collaboration is positively signicant in models (5) and (7), where
the dependent variable is the probability of success in the discovery stage of innovation.
Therefore, projects conducted in collaboration are more likely to complete the discovery
stage successfully and move to the development stage. At the same time, collaboration
does not play a signicant role in the development stage of innovation.
To summarize, the results reported in table 3 conrm hypotheses 3 and 4, namely,
the eect of concentration on the probability of success was positive in the discovery
and negative in the development stages. Furthermore, hypothesis 2 is also conrmed:
economies of scale are positively signicant in the development, but not in the discovery
stages (models (3) and (4)). Nevertheless, we found no evidence in favor of hypothesis
1. Finally, the coecients and the signicance of the variables varies for the stages of
discovery and development. Additionally, the goodness of t is better in the success-in-
discovery estimation8.
7 Conclusion
In this paper, we looked at innovation as a process transforming an idea into a marketable
product. It has been demonstrated that not only factors of a distinct nature (e.g. internal
and external) dene innovation success, but also that the eect of these factors changes
during the course of innovation.
It have also been argued that technological factors, mainly connected to inter- and
intra-rm spillovers, are more important for the success of a drug project in the discovery
stage of innovation, whereas competition factors become more important for the project
success in the development stage. Indeed, the results of the empirical estimation show that
success in various innovation stages is aected by similar factors dierently. Specically,
competition has a stronger impact when analyzing project success in the development
stage. At the same time, technological opportunities seem to be more important in
explaining success in the discovery stage, while collaboration is important in the discovery
but not in development stage.
8To assess regression t, one should look at the Brier score and the area under the ROC curve (ROC).
ROC value close to 1 represents a very good t. Brier score measures the accuracy of a set of probability
assessments. It is equal to the average squared deviation between predicted probabilities and actual
outcomes, therefore higher accuracy is connected to a lower score.
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the discovery stage. In other words, rms with large R&D portfolios bring more projects
into clinical trials than rms with a smaller number of R&D projects. Inrelation to the
development stage, scale economies are correlated with a lower project success. Therefore,
larger R&D portfolios are less benecial in development than in discovery. These results
support the idea of the variable importance of dierent factors during the innovation
process. Furthermore, these results show, in particular, that although scale economies can
be benecial when trying to implement a novel idea in the discovery stage of innovation,
they can have a negative eect on the project's success in the development stage. This
negative result in the development stage repeats the nding of diseconomies of scale by
Danzon et al. (2005). These diseconomies of scale could be explained by the diculties of
managing a large R&D project portfolio, as much as with the lower amount of xed costs
to be shared among projects. In fact, as most of the project portfolios in our sample are
highly diversied (look at the correlation between the variables "scope" and "scale" in
table 4 of the Appendix), the costs of the clinical trials (development stage) are unlikely
to be shared. Moreover, as success is connected to the event of moving to the next stage
(which in the case of development is approval or market launch), the lower success rate for
larger R&D portfolios could also signify a better selection of projects by more established
rms.
The behavior of the scope economies variable is not consistent with the usual beliefs
about the eect of internal spillovers of the rm: specically, scope economies have a
negative impact on project's success in the discovery stage. At the same time, they have
a positive eect on the this success in the development stage of innovation. This nding
may be due to the fact that the "scale" variable wields most of the explanatory power.
In other words, since R&D portfolios are quite diversied, the measure of the eect of
the two variables could be biased due to multicollinearity. The interaction between scope
and scale economies showed that, indeed, a project performed by a rm with a large and
diversied R&D portfolio is less successful in the development stage. However, this result
may be due to quite aggregated denition of a project which we use (i.e., at the level of
therapeutic areas).
Finally, it is important to note that the eect of economies of scale and scope on a
project's success is not signicant when controlling for industry factors, with an exception
for the eect of scope economies on the probability of success in the development stage.
This observation not only suggests that industry characteristics might be more relevant in
explaining a project's progress, but also that there exist other determinants of a project's
success. For example, it could be that, related to strategic considerations, rms consider
their innovation activity in terms of their R&D portfolio rather than as a specic project.
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maximizing the gains on a spacica project. In this context, the strategy of diversied
discovery could be supported in order for a rm to allow for better selection of the
promising directions of innovation.
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collaboration 0.0964 0.1059 1
(0) (0)
concentration 0.129 0.1105 0.0213 1
(0) (0) (0.3657)
competitors 0.1694 0.1768 0.0183 0.7084 1
(0) (0) (0.4278) (0)
experience 0.4113 0.4828 0.1005 0.2616 0.345 1
(0) (0) (0) (0) (0)
Signicance levels in parentheses
Table 5: Logit Estimation of the Probability of Success
Separate Estimations for Collaboration, Concentration and Competition
(1) (2) (3) (4) (5) (6)








experience 0.582*** -0.189*** 0.152** 0.0776** 0.425*** 0.0634
-0.108 -0.0568 -0.066 -0.0385 -0.109 -0.0458
Observations 1835 1509 1769 1459 1835 1509
Clusters 560 475 551 469 560 475
Log Likelihood -1021.4863 -956.3384 -819.39902 -744.4316 -1032.4508 -855.6173
ROC 0.5839 0.4345 0.5333 0.5602 0.5027 0.527
Brier score 0.198 0.2165 0.1668 0.1371 0.1977 0.1738
Modied Brier scorey 0.1981 0.2158 0.1669 0.1373 0.1972 0.1733
LR-test reject "H0" reject "H0" reject "H0" reject "H0" reject "H0" reject "H0"
p-value 0.001 0.001 0.001 0.001 0.001 0.001
Robust standard errors in parentheses *** p<0.01, ** p<0.05, * p<0.1
y Sanders-modied Brier score
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